Virtu Financial LLC Buys Shares of 22,620 Genmab A/S Sponsored ADR $GMAB

Virtu Financial LLC purchased a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 22,620 shares of the company’s stock, valued at approximately $697,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its holdings in Genmab A/S by 124.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after acquiring an additional 1,174 shares during the last quarter. Sei Investments Co. lifted its holdings in Genmab A/S by 4.2% during the second quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock valued at $1,283,000 after purchasing an additional 2,496 shares during the last quarter. Squarepoint Ops LLC boosted its position in Genmab A/S by 636.3% during the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after purchasing an additional 81,434 shares during the period. Quantinno Capital Management LP boosted its position in Genmab A/S by 64.9% during the second quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock worth $3,267,000 after purchasing an additional 62,226 shares during the period. Finally, Raymond James Financial Inc. increased its stake in shares of Genmab A/S by 48.1% in the second quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock worth $643,000 after purchasing an additional 10,113 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Genmab A/S stock opened at $25.61 on Tuesday. The firm’s 50 day simple moving average is $26.44 and its 200 day simple moving average is $28.95. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $15.97 billion, a PE ratio of 19.40, a price-to-earnings-growth ratio of 1.50 and a beta of 0.85. Genmab A/S Sponsored ADR has a 1-year low of $20.23 and a 1-year high of $35.43.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on GMAB shares. Truist Financial initiated coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Genmab A/S in a report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price objective for the company. Weiss Ratings cut shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Finally, Wolfe Research initiated coverage on Genmab A/S in a report on Friday, March 27th. They issued an “outperform” rating and a $32.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and a consensus target price of $37.93.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.